Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)
Launched by VERTEX PHARMACEUTICALS INCORPORATED · Nov 19, 2024
Trial Information
Current as of June 27, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Key Inclusion Criteria:
- • • Completed the final visit in the Treatment Period (i.e., Week 12) and subsequent 7-day period (to allow for taper of blinded capsule study drug) in a parent study such as VX24-548-110 or VX24-548-111
- Key Exclusion Criteria:
- • Any sensory abnormality (excluding DPN)
- • History of drug intolerance in a parent study that would pose an additional risk to the participant in the opinion of the investigator
- • Current participation in an investigational drug trial (other than a parent study)
- • Other protocol defined Inclusion/Exclusion criteria may apply.
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated is a global biotechnology company dedicated to the innovation and development of transformative therapies for serious diseases, particularly those with significant unmet medical needs. Founded in 1989 and headquartered in Boston, Massachusetts, Vertex specializes in the research and commercialization of treatments for cystic fibrosis and other genetic disorders. Leveraging cutting-edge science and a commitment to patient-centric solutions, Vertex collaborates with healthcare professionals and researchers to advance clinical trials and bring groundbreaking therapies to market, aiming to improve the lives of patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Winston Salem, North Carolina, United States
Media, Pennsylvania, United States
Fresno, California, United States
Anniston, Alabama, United States
Jacksonville, Florida, United States
Boston, Massachusetts, United States
Hazelwood, Missouri, United States
Richmond, Virginia, United States
Sacramento, California, United States
East Syracuse, New York, United States
Kansas City, Missouri, United States
Flossmoor, Illinois, United States
Pomona, California, United States
Cincinnati, Ohio, United States
Waltham, Massachusetts, United States
Salt Lake City, Utah, United States
Lexington, Kentucky, United States
Marlton, New Jersey, United States
Maitland, Florida, United States
Bellevue, Washington, United States
Medford, Oregon, United States
Chicago, Illinois, United States
East Greenwich, Rhode Island, United States
Dallas, Texas, United States
West Jordan, Utah, United States
Fort Myers, Florida, United States
Meridian, Idaho, United States
Wichita, Kansas, United States
Charleston, South Carolina, United States
New York, New York, United States
Evansville, Indiana, United States
Anderson, South Carolina, United States
Hallandale Beach, Florida, United States
Albuquerque, New Mexico, United States
Coral Gables, Florida, United States
Morehead City, North Carolina, United States
Scottsdale, Arizona, United States
Long Beach, California, United States
Round Rock, Texas, United States
Thousand Oaks, California, United States
Spartanburg, South Carolina, United States
San Antonio, Texas, United States
Waco, Texas, United States
Baton Rouge, Louisiana, United States
Norfolk, Nebraska, United States
Beachwood, Ohio, United States
Decatur, Georgia, United States
Washington, District Of Columbia, United States
Miami Lakes, Florida, United States
Daphne, Alabama, United States
Los Angeles, California, United States
Deland, Florida, United States
Largo, Florida, United States
New Port Richey, Florida, United States
Orlando, Florida, United States
Winter Park, Florida, United States
Covington, Louisiana, United States
San Bernardino, California, United States
Miami, Florida, United States
Brooklyn, New York, United States
Raleigh, North Carolina, United States
Miami, Florida, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported